These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32125468)

  • 1. Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion.
    Yoshihara K; Yoshihara S; Matsuda I; Imado T; Matsuo S; Okada M; Shimizu Y; Hirota S; Fujimori Y
    Ann Hematol; 2020 Jun; 99(6):1405-1407. PubMed ID: 32125468
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma.
    Ahn JS; Okal R; Vos JA; Smolkin M; Kanate AS; Rosado FG
    J Clin Pathol; 2017 Sep; 70(9):775-780. PubMed ID: 28249941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation.
    Vaxman I; Visram A; Kapoor P; Kumar S; Dispenzieri A; Buadi F; Dingli D; Muchtar E; Gonsalves W; Rajkumar V; Kourelis T; Warsame R; Lacy M; Gertz MA
    Am J Hematol; 2021 Jan; 96(1):E35-E38. PubMed ID: 33068019
    [No Abstract]   [Full Text] [Related]  

  • 4. Extramedullary sarcomatoid variant of plasmablastic plasmacytoma.
    Majhi U; Sundersingh S; Murhekar K; Radha K
    J Cancer Res Ther; 2017; 13(6):1078-1079. PubMed ID: 29237987
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.
    Chen BJ; Yuan CT; Yang CF; Ho CH; Lin YK; Su YZ; Chou HC; Chuang SS
    Virchows Arch; 2022 Aug; 481(2):283-293. PubMed ID: 35657404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
    Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
    Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management.
    Lee J; Smith D; Rabin N; Tobias J; Yong K
    Hematol Oncol; 2016 Sep; 34(3):165-70. PubMed ID: 26073569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Plasmablastic lymphoma presenting clinical symptoms similar to plasmablastic myeloma].
    Nakaya A; Nagate Y; Toda J; Yamashita Y; Hirose Y; Mori K; Shibayama H
    Rinsho Ketsueki; 2023; 64(4):260-264. PubMed ID: 37121769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
    Lodé L; Eveillard M; Trichet V; Soussi T; Wuillème S; Richebourg S; Magrangeas F; Ifrah N; Campion L; Traullé C; Guilhot F; Caillot D; Marit G; Mathiot C; Facon T; Attal M; Harousseau JL; Moreau P; Minvielle S; Avet-Loiseau H
    Haematologica; 2010 Nov; 95(11):1973-6. PubMed ID: 20634494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow infiltration by plasmablastic neoplasm: plasmablastic myeloma or plasmablastic lymphoma?
    Eladl E; Chang H
    Blood; 2021 Mar; 137(9):1268. PubMed ID: 33661296
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma.
    Marrero WD; Cruz-Chacón A; Castillo C; Cabanillas F
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e275-e277. PubMed ID: 29753690
    [No Abstract]   [Full Text] [Related]  

  • 12. SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target.
    Shi J; Bodo J; Zhao X; Durkin L; Goyal T; Meyerson H; Hsi ED
    Br J Haematol; 2019 Apr; 185(1):145-147. PubMed ID: 29785767
    [No Abstract]   [Full Text] [Related]  

  • 13. Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review.
    Mori H; Fukatsu M; Ohkawara H; Oka Y; Kataoka Y; Taito S; Ikezoe T
    Int J Hematol; 2021 Dec; 114(6):639-652. PubMed ID: 34462886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma.
    Yamada T; Hara T; Goto N; Iwata H; Tsurumi H
    Int J Hematol; 2019 Jun; 109(6):723-730. PubMed ID: 30859398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Endotracheal Plasmablastic Lymphoma.
    Bots EMT; Opperman J; Bassa F; Koegelenberg CFN
    Respiration; 2019; 98(6):546-550. PubMed ID: 31634891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma.
    Umeanaeto O; Gamboa J; Diaz J; Hakim MN; Corral J; Philipovskiy A; Gaur S
    Anticancer Res; 2019 Sep; 39(9):5003-5007. PubMed ID: 31519607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?
    Beltran BE; Quiñones P; Sanchez G; Paredes A; Moises C; Cotrina E; Torres-Cabala CA; Miranda RN; Castillo JJ
    Leuk Lymphoma; 2018 Jul; 59(7):1753-1755. PubMed ID: 29081245
    [No Abstract]   [Full Text] [Related]  

  • 18. Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma.
    Marini C; Baldaia H; Trigo F; Castillo JJ
    Am J Hematol; 2016 Aug; 91(8):E324. PubMed ID: 27012155
    [No Abstract]   [Full Text] [Related]  

  • 19. CD3-positive plasmablastic lymphoma reported in two cases: A potential diagnostic caveat.
    Wong YP; Masir N; Chew MX
    Indian J Pathol Microbiol; 2021; 64(3):579-583. PubMed ID: 34341278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmablastic lymphoma with unfavorable chromosomal abnormalities related to plasma cell myeloma: A borderline case between plasmablastic lymphoma and plasmablastic plasma cell myeloma.
    Aoyama Y; Tsunemine H; Kodaka T; Oda N; Matsuoka H; Itoh T; Takahashi T
    J Clin Exp Hematop; 2017; 57(1):37-39. PubMed ID: 28679965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.